peter, you don't get it do you (and I still own part of my position here which I wish I had sold). REAL companies don't have to resort to #$%$ like this, i.e. hiring sleezy firms to pump their stocks on message boards and websites like SA and others. REAL CEOs focus on running and their businesses. if the drug is legit it will be huge and the stock will take care of itself. The sleezy actions highlighted in the terrific SA article call into question everything the company has said about their prospects. management that would stoop to these levels are capable of anything. Get it?
ik4763, you mean in your humble opinion of one. As I told folks about AMRN, NEVER ignore what the market is telling you about a stock or a company's prospects. The smart money isn't always right but is more often than not and right now SNSS market cap is 5X that of CYCC so the street does not share your thoughts that CYCC's drug is better. Don't fall in love with an investment.
I am not concerned. market rolled again this afternoon and looks like the sector as well
The writer responded to my post and at least admitted that he must have taken the wrong revenue for MDXG..he said he pulled it from Google Finance. I suggested that if he is going to publish articles, he might want to pull financial information from the singular source that can be relied on, 10Ks and 10Qs.
Sales from products for 2013 $35 million higher for MDXG than OSIR, $59 million vs $24 million and the author says $3 million? New math? LOL
Correct. OSIR lost money for 2013 from continuing ops and two analyst have them losing i think 23 cents per share in 2014. MDXG analysts have them losing one penny this year but I look for that to be revised to be positive
LOL tiny. Tell that to AMZN sporing a $140 billion market cap with no profits to show. The market doesn't care because it recognizes that AMZN is building its business and that profits will come later in leaps and bounds as it will for MDXG. Right now in the growth phase its about revenue growth and dominating the space as MDXG is starting to do.
11:00 Eastern time at Canaccord. There is a March 2014 presentation in the investor section of the MDXG website which I assume is the presentation. Can also go to the link on website and listen to the presentation. I can't make it but if anyone can and can post any good Q&A here that would be great
OSIR had Q4 revs of $8 million compared to what, $18 million for MDXG? $24 million for 2013 for OSIR and $59 million for MDXG...and the distance in 2014 will likely grow
Article is funny. As I posted there the guy is comparing valuation as if Epifix is MDXG's only product. Then he claims that MDXG revenue is only $3 million more than OSIR for 2013. What am I missing? I see OSIR 2013 revenue of $24.3 million from product sales and MDXG had $59.1 million. Am I missing something ot is that new "OSIR math"?
Look at the Form 4s for the execs..that is the only authoritative information
1. Title of Derivative Security
Restricted Stock Units
( 1 )SIGA Technologies, Inc. (the "Issuer") has certain tax withholding obligations associated with the vesting of restricted stock units ("RSUs") and the consequent issuance of Common Stock of the Issuer. This Form 4 reports the surrender to the Issuer by the Reporting Person of 9,009 shares of Common Stock -- granted in the form of RSUs approximately two years ago -- in order to satisfy those withholding tax obligations. The Reporting Person reported the initial grant on March 1, 2012.
( 2 )Represents vesting of one-third of RSUs granted on February 28, 2012. The remaining 1/3 of such RSUs vest on February 28, 2015. Each RSU converts into one share of Common Stock of the Issuer on a one for one basis.
No they are not options. They are restricted stock grants that vested. No such thing as a zero option. They had restricted stock grants that vested. When that happens, you owe income tax on the value of the shares on the date they vest. You can either pay the tax out of pocket by cutting a check or surrender shares to pay the tax,.i.e. surrender 28% of shares to cover the tax which is what you see on their Form 4s
You mean like ICPT with one product and a $ 8 billion market cap? Why don't you pump your investment on its board instead of being a spammer?
I am familiar with CYCC ik4763. I'll pass, Why are you here hyping CYCC like a paid spammer? No reason for you to be here unless you are short SNSS and if so, your agenda renders you irrelevant.
from December 5th cc
Matt G. Hewitt – Craig-Hallum Capital Group LLC
Good morning gentlemen, couple of questions from me. First, regarding the BLA and IND process, it sounds like that it’s going to take several months to working with the FDA regarding some enlargement of details there, but once you start that, essentially Phase 3 trial, how long do you anticipate that that will take, what type of cost do you anticipate being associated with that process and when should we anticipate maybe a word from the FDA on whether or not you have been granted biologic licenses?
William C. Taylor
Matt, we will give more specifics to that shortly, but in general, we are talking a period of probably two plus years in the case of our tissue because speaking the results, we get so dramatic over standard of care, there’s not going to be huge numbers of patients in these studies.
So from that standpoint all that moves faster than normal. But allowed this work is work done in the I&D process getting ready, getting adequate staff count with the study and our proposals to make the study et cetera. And in along those lines in the next several months some of our business will be very focused on our micronized safety data, our clinical outcomes, our clinical papers and coverage papers et cetera. As I again to make some decisions in terms of development of the transition playing for us.
You asked for costs? I would say, probably north of $1 million a piece.